Opinion
Video
Author(s):
The expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC
Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
The OncFive: Top Oncology Articles for the Week of 1/19
Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48
Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC
Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC
Darolutamide Plus ADT Is Efficacious in mHSPC Regardless of Disease Volume
EBRT With or Without STAD Shows Improved 15-Year Survival in Prostate Cancer
Composite Gene Expression Score Shows Potential to Predict Bavdegalutamide Benefit in mCRPC